Xilio Therapeutics Overview
- Founded
-
2016
- Status
-
Public
- Employees
-
89
- Stock Symbol
-
XLO
- Share Price
-
$3.19
- (As of Tuesday Closing)
Xilio Therapeutics General Information
Description
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index.
Contact Information
- 828 Winter Street
- Suite 300
- Waltham, MA 02451
- United States
Xilio Therapeutics Timeline
Xilio Therapeutics Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.19 | $3.12 | $1.95 - $4.92 | $85.7M | 27.5M | 29.8K | -$3.22 |
Xilio Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | (45,146) | (45,146) | 583,293 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (86,375) | (86,375) | (74,301) | (54,154) |
| Net Income | (88,222) | (88,222) | (75,800) | (55,219) |
| Total Assets | 139,165 | 139,165 | 218,060 | 36,317 |
| Total Debt | 19,939 | 19,939 | 20,536 | 21,217 |
Xilio Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xilio Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Xilio Therapeutics Comparisons
Industry
Financing
Details
000000
000000
Xilio Therapeutics Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Werewolf Therapeutics | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 00000000 000 | Formerly VC-backed | Somerville, MA | 000 | 00000 | 000000000 | 00000 |
Xilio Therapeutics Executive Team (16)
Xilio Therapeutics Board Members (24)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christina Rossi | Self | Board Member | 000 0000 |
| Daniel Curran | Takeda Ventures | Board Member | 000 0000 |
| Daniel Lynch | Self | Chairman of the Board | 000 0000 |
| Michael Ross Ph.D | SV Health Investors | Board Member | 000 0000 |
| Paul Clancy | Self | Chairman & Board Member | 000 0000 |
Xilio Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Xilio Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Xilio Therapeutics ESG
Risk Overview
Risk Rating
Updated July, 19, 2022
31.81 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,912
Rank
Percentile
Pharmaceuticals
Industry
00 of 965
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 455
Rank
Percentile
